Search Results - "Williams, Cathy D" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

$Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia$

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

by Wierda, William G, Kipps, Thomas J, Mayer, Jirí, Stilgenbauer, Stephan, Williams, Cathy D, Hellmann, Andrzej, Robak, Tadeusz, Furman, Richard R, Hillmen, Peter, Trneny, Marek, Dyer, Martin J S, Padmanabhan, Swami, Piotrowska, Magdalena, Kozak, Tomas, Chan, Geoffrey, Davis, Randy, Losic, Nedjad, Wilms, Joris, Russell, Charlotte A, Osterborg, Anders
Published in Journal of clinical oncology (01.04.2010)

Get full text

Journal Article

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

by Jackson, Graham H, Pawlyn, Charlotte, Cairns, David A, de Tute, Ruth M, Hockaday, Anna, Collett, Corinne, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Drayson, Mark T, Gregory, Walter M, Kaiser, Martin F, Owen, Roger G, Davies, Faith E, Morgan, Gareth J
Published in PLoS medicine (01.01.2021)

Get full text

Journal Article

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Allotey, David, Shafeek, Salim, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Morgan, Gareth J, Clinical Studies Group, Uk Ncri Haematological Oncology
Published in Haematologica (Roma) (01.07.2021)

Get full text

Journal Article

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

by Cook, Gordon, Ashcroft, A John, Cairns, David A, Williams, Cathy D, Brown, Julia M, Cavenagh, Jamie D, Snowden, John A, Parrish, Christopher, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M, Pratt, Guy, Chown, Sally, Heartin, Ernest, O'Connor, Sheila, Drayson, Mark T, Hockaday, Anna, Morris, Treen C M
Published in The Lancet. Haematology (01.07.2016)

Get more information

Journal Article

$Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study$

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

by Österborg, Anders, Jewell, Roxanne C, Padmanabhan-Iyer, Swami, Kipps, Thomas J, Mayer, Jiří, Stilgenbauer, Stephan, Williams, Cathy D, Hellmann, Andrzej, Furman, Richard R, Robak, Tadeusz, Hillmen, Peter, Trnêný, Marek, Dyer, Martin J S, Piotrowska, Magdalena, Kozak, Tomas, Gupta, Ira V, Phillips, Jennifer L, Goldstein, Nancy, Struemper, Herbert, Losic, Nedjad, Lisby, Steen, Wierda, William G
Published in Haematologica (Roma) (01.08.2015)

Get full text

Journal Article

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Hockaday, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Morgan, Gareth J
Published in The lancet oncology (01.01.2019)

Get full text

Journal Article

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

by Jordan, Karin, Proskorovsky, Irina, Lewis, Philip, Ishak, Jack, Payne, Krista, Lordan, Noreen, Kyriakou, Charalampia, Williams, Cathy D., Peters, Sarah, Davies, Faith E.
Published in Supportive care in cancer (01.02.2014)

Get full text

Journal Article

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma

by Proskorovsky, Irina, Lewis, Philip, Williams, Cathy D, Jordan, Karin, Kyriakou, Charalampia, Ishak, Jack, Davies, Faith E
Published in Health and quality of life outcomes (11.03.2014)

Get full text

Journal Article

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial

by Jackson, Graham H., Pawlyn, Charlotte, Cairns, David A., Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R., Wilson, Jamie, Taylor, Craig, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D., Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W., Cook, Gordon, Russell, Nigel H., Drayson, Mark T., Kaiser, Martin F., Owen, Roger G., Gregory, Walter M., Davies, Faith E., Morgan, Gareth J.
Published in British journal of haematology (01.03.2021)

Get full text

Journal Article

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

by Cook, Gordon, Royle, Kara‐Louise, O'Connor, Sheila, Cairns, David A., Ashcroft, A. John, Williams, Cathy D., Hockaday, Anna, Cavenagh, Jamie D., Snowden, John A., Ademokun, Debo, Tholouli, Eleni, Andrews, Vivienne E., Jenner, Matthew, Parrish, Christopher, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M., Pratt, Guy, Drayson, Mark T., Brown, Julia M., Morris, Treen C. M.
Published in British journal of haematology (01.05.2019)

Get full text

Journal Article

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, Morgan, Gareth J
Published in The Lancet. Haematology (01.12.2019)

Get more information

Journal Article

$Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma$

Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma

by Sidra, G, Williams, CD, Russell, NH, Zaman, S, Myers, B, Byrne, JL
Published in Haematologica (Roma) (01.06.2006)

Get full text

Journal Article

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial

by Parrish, Christopher, Morris, Curly T.C.M, Williams, Cathy D, Cairns, David A, Cavenagh, Jamie, Snowden, John A, Ashcroft, John, Cavet, Jim, Hunter, Hannah, Bird, Jenny M, Chalmers, Anna, Brown, Julia M, Yong, Kwee, Schey, Steve, Chown, Sally, Cook, Gordon
Published in Biology of blood and marrow transplantation (01.06.2016)

Get full text

Journal Article

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide : Interim analysis of an open-label randomised controlled trial

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide : Interim analysis of an open-label randomised controlled trial

by Jackson, Graham H, Pawlyn, Charlotte, Cairns, David A, de Tute, Ruth M, Hockaday, Anna, Collett, Corinne, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Drayson, Mark T, Gregory, Walter M, Kaiser, Martin F, Owen, Roger G, Davies, Faith E, Morgan, Gareth J
Published in PLoS medicine (11.01.2021)

Get full text

Journal Article

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide

by Jackson, Graham H, Pawlyn, Charlotte, Cairns, David A, de Tute, Ruth M, Hockaday, Anna, Collett, Corinne, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Drayson, Mark T, Gregory, Walter M, Kaiser, Martin F, Owen, Roger G, Davies, Faith E, Morgan, Gareth J
Published in PLoS medicine (11.01.2021)

Get full text

Journal Article

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid® Treatment Continuation Scheme™ (TCS)

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid® Treatment Continuation Scheme™ (TCS)

by Williams, Cathy D., Simcock, Mathew, Lodhi, Imran, Robinson, Suzanne K., Davies, Faith E.
Published in Blood (16.11.2012)

Get full text

Journal Article

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

by Ahmedzai, Sam H, Snowden, John A, Cox, Angela, Cairns, David A, Williams, Cathy D, Hockaday, Anna, Cavenagh, Jamie, Parrish, Christopher, Yong, Kwee L, Cavet, Jim, Hunter, Hannah, Bird, Jennifer, Ashcroft, John, Brown, Julia, Morris, Curly, Cook, Gordon
Published in Blood (03.12.2015)

Get full text

Journal Article

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, Morgan, Gareth J
Published in Blood (02.12.2016)

Get full text

Journal Article

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, Morgan, Gareth J
Published in Blood (02.12.2016)

Get full text

Journal Article

$Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study$

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

by Pawlyn, Charlotte, Davies, Faith E, Kaiser, Martin F, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, Jackson, Graham H, Morgan, Gareth J
Published in Blood (02.12.2016)

Get full text

Journal Article